Our deep scientific understanding of the infant gut microbiome and nutrition led to the development of Evivo infant probiotic —containing a powerful ingredient that matters most to newborns: B. infantis EVC001.
B. infantis EVC001, the proprietary strain in Evivo, when paired with human milk, transforms the preterm infant’s ability to metabolize HMOs. This synergy of Evivo and human milk is essential in supporting the development of a healthy microbiome, supporting immune system development, and moderating inflammation.
Delivering Evivo Infant Probiotic with B. infantis EVC001 helps to maximize protection from within during a vulnerable period of time for patients. It enables infants to more effectively and efficiently utilize the nutrients found in human milk, supporting their health and development.
Studies have shown that B. infantis EVC001 is the only strain clinically shown to:
Evivo Infant Probiotic is an important tool to enhance feeding protocols for all infants. Feeding NICU babies B. infantis EVC001 in Evivo can modulate enteric inflammation by reducing potential gut pathogens and concurrently increasing beneficial bifidobacteria in the preterm gut.
Given once a day orally or through a feeding tube, Evivo MCT oil has been shown to be well tolerated by preterm infants. By ensuring that your patients are exposed to B. infantis, you can support their gut health and immune development and help set them on a course to better health.
Evivo Infant Probiotic contains only high-quality ingredients from reputable sources. Each lot is manufactured in the U.S. and passes multiple tests for quality, safety, and viability. Evivo has earned "Clean Label Project” and “First 1,000 Day Promise” certifications from the Clean Label Project.
Evivo is manufactured using high-quality ingredients in an FDA-compliant, inspected, and regulated setting. Products are further protected by cold chain distribution and stored in a freezer until feeding.
Clinical research shows that B. infantis EVC001, the single powerful ingredient in Evivo, has a remarkable synergy with human milk that creates the system intended to nourish and help protect infants.
B. infantis EVC001 helps transform human milk oligosaccharides (HMOs) into organic molecules that human cells can absorb, providing more available nutrients. Without B. infantis EVC001, research published in mSphere and Frontiers in Pediatrics shows these HMOs, unabsorbed, go into the stool.
B. infantis EVC001 converts HMOs into key signaling molecules called metabolites. Recent research published in Cell, shows these metabolites promote healthy gut function and help program immune cells to be tolerant instead of over-reactive.
Research published in Frontiers in Pediatrics shows that preterm infants fed B. infantis EVC001 along with human milk as standard of care report lower levels of fecal proinflammatory cytokines and less antibiotic resistant genes in the microbiome.
Dr. Erin Qualter works to improve the health of all babies. Watch as she explains how Evivo pairs with human milk to create a protective environment in your baby’s GI tract, helping to support overall immune health.
The environment in your baby’s gut is training its immune system. Our immunologist, Bethany Henrick, Ph.D, shares the importance of nurturing your baby’s gut and how the good bacteria B. infantis EVC001, only available in Evivo, can help.
As a NICU nurse, Carrie McGuckin has seen the benefits of Evivo® first-hand. Watch as she shares her experience and the results other facilities are seeing.
Dr. Erin Qualter works to improve the health of all babies. Watch as she explains how Evivo pairs with human milk to create a protective environment in your baby’s GI tract, helping to support overall immune health.
The environment in your baby’s gut is training its immune system. Our immunologist, Bethany Henrick, Ph.D, shares the importance of nurturing your baby’s gut and how the good bacteria B. infantis EVC001, only available in Evivo, can help.
As a NICU nurse, Carrie McGuckin has seen the benefits of Evivo® first-hand. Watch as she shares her experience and the results other facilities are seeing.
Neonatologist Jennifer Bragg shares why she advocates for the regular use of EVC001 in all babies.
NICU Nurse Sandy Bradbury talks about Evivo®’s impact on babies from the start, helping to protect them from the inside out.
Dr. German is a Distinguished Professor and Chemist at the University of California, Davis and Director of its Foods for Health Institute located in the Robert Mondavi Institute. He has had a long and highly distinguished career focused on understanding the role of food and certain food ingredients in delivering improved health. His research investigates how to improve foods and their ability to facilitate improved health. His lab group seeks to discover physical, functional, and nutritional components of human milk.
Dr. German’s particular expertise is the nutrient delivery between mothers and infants in the first few months of life. A co-founder of Infinant Health, he has received numerous awards in recognition of his discoveries and has served as an expert advisor to the world's leading food and nutrition companies and organizations.
Dr. Mills is a Distinguished Professor in the Departments of Food Science and Technology and Viticulture and Enology and holds the Peter J. Shields Chair in Dairy Food Science at the University of California, Davis. He received his PhD from the University of Minnesota and completed postdoctoral studies at North Carolina State University. He studies the molecular biology and ecology of bacteria that play an active role in gut health or fermented foods and beverages.
In the last 24 years, Dr. Mills has mentored over 30 graduate students and postdocs and has generated more than 210 publications, including seminal work on lactic acid bacterial and bifidobacterial genomics. He has worked to define, investigate, and translate the beneficial aspects of human milk and its role in human health. A co-founder of Infinant Health, Dr. Mills has previously served as a Distinguished Lecturer for the American Society for Microbiology where he was elected as a fellow and currently serves on the editorial board of Applied and Environmental Microbiology.
Dr. Lebrilla is a Distinguished Professor at the University of California, Davis in the Department of Chemistry and Biochemistry and in Molecular Medicine at its School of Medicine. He received his PhD from the University of California, Berkeley and was the Alexander von Humboldt Fellow and NSF/NATO Fellow at the Technical University in Berlin. His research focuses on developing bioanalytical methods based on mass spectrometry with the goals of structurally characterizing bioactives in food and determining their relationships to health and diseases. He has created techniques for the characterization of milk bio actives, most specifically mammalian milk oligosaccharides. He has published over 450 papers and has been cited over 30,000 times.
Dr. Lebrilla is co-chief editor of Mass Spectrometry Reviews and has served on the editorial boards of Molecular and Cellular Proteomics, Mass Spectrometry Reviews, Journal of the American Society for Mass Spectrometry, European Mass Spectrometry, and the International Journal of MassS pectrometry. He is a co-founder of Infinant Health and has co-founded other biotech companies focusing on bioactive foods and biomarkers for early disease diagnosis.
Dr. Barile is a Professor in the Department of Food Science and Technology at the University of California, Davis. For the past 13 years, her research has centered on the chemical and biological properties of milk, with a focus on small molecules, to generate novel ingredients that can modulate the gut microbiome. The Barile Lab has established a high-throughput platform based on mass spectrometry for rapid-throughput analysis of microbiome-modulating compounds such as glycoproteins, glycans, and glycolipids as well as antimicrobial peptides. Her approach of sequential molecular deconstruction of human donor milk and dairy streams has generated valuable bioinformatic libraries of source materials and fundamental information on the underlying biological and processing conditions that give rise to their formation, preservation, and interaction with the gut microbiome.
Dr. Barile has expanded her analytical work through a series of collaborative studies in animal models and in vitro, documenting selective stimulation of protective gut bacteria and investigating the interaction with pathogenic species. She is principal investigator and co-principal investigator on several USDA and NIH-funded grants on prebiotics/probiotics. The highly collaborative aspect of her research is evidenced by the publication of over 120 research manuscripts in leading peer-reviewed food science and nutrition journals, which have been cited over 4,000 times in just the last 5 years. She received the 2017 UC Davis Chancellor’s Fellow Award, which is awarded to outstanding faculty members who produce groundbreaking research and scholarship early in their careers. Together with other Infinant Health co-founders, her work has been recognized by selection as the 2014 Dean's Team Award for Excellence for Outstanding Multidisciplinary Research Contributions and the 2020 UC Davis Chancellor’s Innovator of the Year Award.
Dr. Freeman received a Ph.D. in gastrointestinal physiology from the University of Calgary before completing postdoctoral training at the University of California, Davis. While there, she became interested in how science and technology successfully create real-world value. She completed a certificate in business development from the Graduate school of Management at the University of California, Davis, to work at the forefront of the successful translation of research from science to market. With this new perspective, she became one of the co-founders of the Milk Bioactives Program and focused on building and managing multidisciplinary teams centered on the translation and commercialization of scientific discoveries from the program.
Dr. Freeman then spent two years as a manager of a national public-private partnership (Foods for Health Ireland) in Ireland before returning to the University of California, Davis, as the Associate Director of Business Development at the Foods for Health Institute and became a co-founder of Infinant Health, to open the door to commercializing the Institute's pioneering technology. She now focuses full-time on the company as the Director of Intellectual Property and Regulatory Affairs to help commercialize the technology developed at the University of California, Davis.